CAS NO: | 205923-56-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
生物活性 | Cetuximab (C225) is a humanIgG1monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with aKdof 0.201 nM forEGFRby SPR. Cetuximab has potent antitumor activity[1]. | ||
IC50& Target[1] |
| ||
体外研究 (In Vitro) | Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kdof 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kdof 0.147 nM for EGFR in fixed A431 cells by ELISA[1]. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3]. | ||
体内研究 (In Vivo) | Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts[2]. | ||
Clinical Trial | |||
分子量 | 145543.35 | ||
性状 | Liquid | ||
CAS 号 | 205923-56-4 | ||
中文名称 | 西妥昔单抗 | ||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |